Targeted drug doubles progression free survival in Hodgkin lymphoma

19 marzo 2015

A phase 3 trial of brentuximab vedotin (BV), the first new drug for Hodgkin lymphoma in over 30 years, shows that adults with hard-to-treat Hodgkin lymphoma given BV immediately after stem cell transplant survived without the disease progressing for twice as long as those given placebo — 43 months vs 24 months.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/tCZTPEC-lPA/150319080452.htm

Volver